Pharma Expansion Leverage Elucidata’s proven pharma traction with Pfizer, Janssen, NextGen Jane and IMBDx to target additional large pharma and biotech customers. Emphasize Polly’s ability to reclaim R&D time by harmonizing multi-modal data into consistent pipelines with granular annotations and rigorous QA/QC, enabling patient stratification, biomarker discovery, and rapid target validation at scale. Frame Polly as the data backbone for regulated analytics and AI workflows, helping shorten trial timelines and improve reproducibility.

AI Labs Synergy Capitalize on AI Labs initiatives to position Polly as a foundation for biomedical AI research. Highlight the platform’s capacity to curate diverse datasets quickly with a human-in-the-loop quality model, enabling faster model training and higher data quality. Propose joint development or co-selling opportunities with existing customers around AI components for drug discovery and translational research.

Real World Data Target Real World Data and EHR integration opportunities for clinical outcomes research and payer ecosystems. Show Polly’s unified data model across Omics, assays, RWD, and EHR data to enable patient stratification, biomarker discovery, and clinical pipeline development. Offer data governance, QA, and reproducible data pipelines as a service to CROs and pharma clients needing compliant, auditable analytics.

Global Delivery Promote the global delivery footprint spanning the US, India R&D hubs and cost-effective delivery for CROs and sponsors. Emphasize scalable support for large multi-modal datasets and complex analyses. Explore partnerships with Indian biotech labs and CROs and reference Almaden Genomics integration as an example of cloud-native omics data science in action.

Differentiation Partnerships Differentiate through Polly’s capabilities like rapid LLM powered curation with human oversight, recognized innovation in biotech, and seasoned leadership. Position these strengths to enable co-development and data licensing partnerships that accelerate customers’ AI and analytics initiatives. Leverage investor and board experience to bolster enterprise sales and long-term collaborations.